NTLA vs. SCHD

Last updated Apr 2, 2026

Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Schwab U.S. Dividend Equity ETF (SCHD).

SCHD is a passively managed fund by Charles Schwab that tracks the performance of the Dow Jones U.S. Dividend 100 Index. It was launched on Oct 20, 2011.

Performance

NTLA vs. SCHD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Schwab U.S. Dividend Equity ETF (SCHD). The values are adjusted to include any dividend payments, if applicable.

NTLA vs. SCHD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NTLA Intellia Therapeutics, Inc.	47.61%	-22.90%	-61.76%	-12.61%	-70.49%	117.35%	270.82%	7.47%	-28.98%	46.61%
SCHD Schwab U.S. Dividend Equity ETF	12.17%	4.34%	11.66%	4.54%	-3.26%	29.87%	15.03%	27.29%	-5.56%	20.85%

Returns By Period

In the year-to-date period, NTLA achieves a 47.61% return, which is significantly higher than SCHD's 12.17% return.

NTLA

• 1D: 3.51%
• 1M: -14.05%
• YTD: 47.61%
• 6M: -29.26%
• 1Y: 99.40%
• 3Y*: -29.12%
• 5Y*: -30.19%
• 10Y*: —

SCHD

• 1D: -0.55%
• 1M: -3.43%
• YTD: 12.17%
• 6M: 12.91%
• 1Y: 13.70%
• 3Y*: 11.84%
• 5Y*: 8.32%
• 10Y*: 12.25%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NTLA vs. SCHD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTLA

NTLA Risk / Return Rank: 70
NTLA Sharpe Ratio Rank: 73
NTLA Sortino Ratio Rank: 72
NTLA Omega Ratio Rank: 75
NTLA Calmar Ratio Rank: 66
NTLA Martin Ratio Rank: 61

SCHD

SCHD Risk / Return Rank: 43
SCHD Sharpe Ratio Rank: 46
SCHD Sortino Ratio Rank: 46
SCHD Omega Ratio Rank: 46
SCHD Calmar Ratio Rank: 39
SCHD Martin Ratio Rank: 38

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NTLA vs. SCHD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Schwab U.S. Dividend Equity ETF (SCHD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NTLA	SCHD	Difference
Sharpe ratio Return per unit of total volatility	0.99	0.88	+0.11
Sortino ratio Return per unit of downside risk	1.74	1.32	+0.42
Omega ratio Gain probability vs. loss probability	1.25	1.19	+0.07
Calmar ratio Return relative to maximum drawdown	1.22	1.05	+0.17
Martin ratio Return relative to average drawdown	2.17	3.55	-1.39
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NTLA vs. SCHD - Sharpe Ratio Comparison

The current NTLA Sharpe Ratio is 0.99, which is comparable to the SCHD Sharpe Ratio of 0.88. The chart below compares the historical Sharpe Ratios of NTLA and SCHD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NTLA	SCHD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.99	0.88	+0.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.38	0.58	-0.96
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.74	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.06	0.84	-0.90

Correlation

The correlation between NTLA and SCHD is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NTLA vs. SCHD - Dividend Comparison

NTLA has not paid dividends to shareholders, while SCHD's dividend yield for the trailing twelve months is around 3.46%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NTLA Intellia Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SCHD Schwab U.S. Dividend Equity ETF	3.46%	3.82%	3.64%	3.49%	3.39%	2.78%	3.16%	2.98%	3.06%	2.63%	2.89%	2.97%

Drawdowns

NTLA vs. SCHD - Drawdown Comparison

The maximum NTLA drawdown since its inception was -96.45%, which is greater than SCHD's maximum drawdown of -33.37%. Use the drawdown chart below to compare losses from any high point for NTLA and SCHD.

Drawdown Indicators

	NTLA	SCHD	Difference
Max Drawdown Largest peak-to-trough decline	-96.45%	-33.37%	-63.08%
Max Drawdown (1Y) Largest decline over 1 year	-71.27%	-12.74%	-58.53%
Max Drawdown (5Y) Largest decline over 5 years	-96.45%	-16.85%	-79.60%
Max Drawdown (10Y) Largest decline over 10 years	—	-33.37%	—
Current Drawdown Current decline from peak	-92.49%	-3.43%	-89.06%
Average Drawdown Average peak-to-trough decline	-56.43%	-3.34%	-53.09%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.98%	3.75%	+36.23%

Volatility

NTLA vs. SCHD - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 17.93% compared to Schwab U.S. Dividend Equity ETF (SCHD) at 2.33%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than SCHD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NTLA	SCHD	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.93%	2.33%	+15.60%
Volatility (6M) Calculated over the trailing 6-month period	85.04%	7.96%	+77.08%
Volatility (1Y) Calculated over the trailing 1-year period	101.32%	15.69%	+85.63%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.73%	14.40%	+66.33%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.27%	16.70%	+61.57%